- Home
- CADL vs SCLXW Comparison
CADL vs SCLXW Comparison
Compare CADL & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- SCLXW
- Stock Information
- Founded
- CADL 1999
- SCLXW N/A
- Country
- CADL United States
- SCLXW United States
- Employees
- CADL N/A
- SCLXW 113
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- SCLXW Health Care
- Exchange
- CADL Nasdaq
- SCLXW Nasdaq
- Market Cap
- CADL N/A
- SCLXW N/A
- IPO Year
- CADL 2021
- SCLXW 2021
- Fundamental
- Price
- CADL $3.80
- SCLXW $0.25
- Analyst Decision
- CADL
- SCLXW
- Analyst Count
- CADL 0
- SCLXW 0
- Target Price
- CADL N/A
- SCLXW N/A
- AVG Volume (30 Days)
- CADL 296.2K
- SCLXW N/A
- Earning Date
- CADL 11-14-2024
- SCLXW N/A
- Dividend Yield
- CADL N/A
- SCLXW N/A
- EPS Growth
- CADL N/A
- SCLXW N/A
- EPS
- CADL N/A
- SCLXW N/A
- Revenue
- CADL N/A
- SCLXW N/A
- Revenue This Year
- CADL N/A
- SCLXW N/A
- Revenue Next Year
- CADL N/A
- SCLXW N/A
- P/E Ratio
- CADL N/A
- SCLXW N/A
- Revenue Growth
- CADL N/A
- SCLXW N/A
- 52 Week Low
- CADL $0.77
- SCLXW N/A
- 52 Week High
- CADL $14.30
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- CADL 16.07
- SCLXW N/A
- Support Level
- CADL $5.12
- SCLXW N/A
- Resistance Level
- CADL $5.43
- SCLXW N/A
- Average True Range (ATR)
- CADL 0.32
- SCLXW 0.00
- MACD
- CADL -0.11
- SCLXW 0.00
- Stochastic Oscillator
- CADL 0.81
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.